

North Carolina Department of Health and Human Services
Division of Medical Assistance
Clinical Policy

2501 Mail Service Center • Raleigh, N. C. 27699-2501 • Tel 919-855-4260

Pat McCrory, Governor

Aldona Z. Wos, M.D.
Ambassador (Ret.)
Secretary DHHS

Sandra Terrell, MS, RN
Acting Director

April 25, 2014

Dr. Aldona Wos,
Secretary of Health and Human Services
N.C. Department of Health and Human Services
101 Blair Drive
Raleigh, N.C. 27603

Dear Secretary Wos,

On behalf of the North Carolina Department of Health and Human Services Medicaid Preferred Drug List Review Panel, I am pleased to present our annual recommendations to you for the North Carolina Medicaid and Health Choice Preferred Drug List. The following recommendations are from clinical reviews completed on January 10, 2014.

The panel reviewed drug classes on the proposed Preferred Drug List (PDL) that were approved by the Pharmacy and Therapeutics committee and the North Carolina Physician Advisory Group. The panel reviewed each drug class in which a decision was needed on preferred versus non-preferred status. Decisions were made with consideration given to the evidence-based data available for each drug class, the written comments received during two 45-day comment periods and the public comments received during the panel meeting. The public comment period was from August 14 to September 28, 2013 and October 16 to November 30, 2013

RECOMMENDATIONS:

The panel recommends approval of the proposed North Carolina Medicaid and Health Choice Preferred Drug List with associated prior authorization criteria as posted during the public comment periods with the following changes:

1. NSAIDS

The panel approves the PDL proposal for NSAIDS with the following change:

- Allow Mobic suspension for patients under 12 years of age without a prior authorization

North Carolina Department of Health and Human Services
Division of Medical Assistance
Clinical Policy

2501 Mail Service Center • Raleigh, N. C. 27699-2501 • Tel 919-855-4260

Pat McCrory, Governor

Aldona Z. Wos, M.D.
Ambassador (Ret.)
Secretary DHHS

Sandra Terrell, MS, RN
Acting Director

2. LONG ACTING NARCOTIC ANALGESICS

The panel approves the PDL proposal for LONG ACTING NARCOTIC ANALGESICS with the following change:

- Allow 1 long acting product with deterrent technology to be preferred based on least cost to the state. The state found that Opana ER® would be this product, so it will stay preferred as in previous years.

3. SHORT ACTING SCHEDULE II NARCOTIC ANALGESICS

The panel approves the PDL proposal for SHORT ACTING SCHEDULE II NARCOTIC ANALGESICS with the following change:

- Move meperidine to non-preferred status

4. SECOND GENERATION ANTICONVULSANTS

The panel approves the PDL proposal for SECOND GENERATION ANTICONVULSANTS with the following change:

- DMA will track utilization and difficulties in obtaining Diastat®

5. BETA BLOCKERS

The panel approves the PDL proposal for BETA BLOCKERS with the following change:

- DMA will track utilization and difficulties in obtaining Toprol XL®

6. INSULIN PRODUCTS

The panel approves the PDL proposal for INSULIN PRODUCTS with the following change:

- Levemir® Quick Pen will be exempt for pregnant women

7. DPP-IV INHIBITORS AND COMBINATIONS

The panel approves the PDL proposal for DPP-IV INHIBITORS AND COMBINATIONS with the following change:

- A 6 month hold on implementation of approved changes so providers can change patients to other therapies

8. SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITOR

North Carolina Department of Health and Human Services
Division of Medical Assistance
Clinical Policy

2501 Mail Service Center • Raleigh, N. C. 27699-2501 • Tel 919-855-4260

Pat McCrory, Governor

Aldona Z. Wos, M.D.
Ambassador (Ret.)
Secretary DHHS

Sandra Terrell, MS, RN
Acting Director

The panel approves the PDL proposal for SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITOR with the following change:

- Make Invokana® a preferred agent

9. ANTIEMETIC-ANTIVERTIGO AGENTS

The panel approves the PDL proposal for ANTIEMETIC-ANTIVERTIGO AGENTS with the following change:

- Diclegis® would be exempt for pregnancy

10. SELECTIVE CONSTIPATION AGENTS

The panel approves the PDL proposal for SELECTIVE CONSTIPATION AGENTS with the following change:

- Exemption for males to use Linzess®

11. URINARY ANTISPASMODICS

The panel approves the PDL proposal for URINARY ANTISPASMODICS with the following change:

- A 6 month hold on implementation of approved changes so providers can change patients to other therapies

12. ORAL ANTICOAGULANTS

The panel approves the PDL proposal for ORAL ANTICOAGULANTS with the following change:

- DMA will track barriers to patient care with keeping Eliquis® non-preferred

13. OPHTHALMIC CARBONIC ANHYDRASE INHIBITORS

The posted PDL for comment showed showing Simbrinza® as non-preferred, but new data supplied by Magellan moved this product to a preferred status.

14. COPD AGENTS

The panel approves the PDL proposal for COPD AGENTS with the following change:

- Change non-preferred requirements for use to only needing to the trial and failure of Spiriva®

North Carolina Department of Health and Human Services
Division of Medical Assistance
Clinical Policy

2501 Mail Service Center • Raleigh, N. C. 27699-2501 • Tel 919-855-4260

Pat McCrory, Governor

Aldona Z. Wos, M.D.
Ambassador (Ret.)
Secretary DHHS

Sandra Terrell, MS, RN
Acting Director

15. VAGINAL ANTIBIOTICS

The panel approves the PDL proposal for VAGINAL ANTIBIOTICS with the following change:

- A 3 month delay before implementing this new PDL class

16. TOPICAL ANTIFUNGALS

The panel approves the PDL proposal for VAGINAL ANTIBIOTICS with the following change:

- Look into OTC products for future PDL placement

17. TOPICAL ANTIPARASITICS

The panel approves the PDL proposal for TOPICAL ANTIPARASITICS with the following change:

- Trial and failure of only one preferred agent needed to obtain a non-preferred agent

18. TOPICAL STEROIDS

The panel approves the PDL proposal for TOPICAL STEROIDS with the following change:

- Derma Smoothe FS® will continue to be a preferred brand

19. ESTROGEN ORAL/TRANSDERMAL AGENTS

The panel approves the PDL proposal for ESTROGEN ORAL/TRANSDERMAL AGENTS with the following change:

- A 6 month hold on implementation of making Premarin® a non-preferred product in this class

20. OPIOD DEPENDENCE

The panel approves the PDL proposal for OPIOD DEPENDENCE with the following change:

- DMA is to try to find a way to cover the Lazarus Kit.

North Carolina Department of Health and Human Services
Division of Medical Assistance
Clinical Policy

2501 Mail Service Center • Raleigh, N. C. 27699-2501 • Tel 919-855-4260

Pat McCrory, Governor

Aldona Z. Wos, M.D.
Ambassador (Ret.)
Secretary DHHS

Sandra Terrell, MS, RN
Acting Director

21. IMMUNOMODULATORS

The panel approves the PDL proposal for IMMUNOMODULATORS with the following change:

- Prior Authorization exemption for Kineret® for diagnosis of Neonatal Onset – Multisystem Inflammatory Disease, (NOMID).

Sincerely,



Jason Swartz, RPh, MBA

Outpatient Pharmacy Program Manager, Division of Medical Assistance

Cc: Dr. Cedric Bright, Representative for the Old North State Medical Society
Dr. Stefanie Ferreri, Representative for the North Carolina Association of Pharmacists
Dr. Paul Bush, Representative for Hospital-Based Pharmacy
Dr. Tom Wroth, Representative for Community Care of North Carolina
Dr. Burt Johnson, Representative for the North Carolina Psychiatric Association
Dr. Lisa Weeks, Representative for the North Carolina Division of Medical Assistance
Dr. Beat Steiner, Representative for the Physician Advisory Group Pharmacy and Therapeutics Committee
Dr. William Sheridan, Representative for Research-Based Pharmaceutical Companies
Dr. Theresa Flynn, Representative for the North Carolina Pediatric Society
Dr. Robert (Chuck) Rich, Representative for the North Carolina Academy of Family Physicians
Dr. Byron Hoffman, Representative for the North Carolina Chapter of the American College of Physicians
Mike Watson, N.C. Division of Medical Assistance
Ms. Sandra Terrell, N.C. Division of Medical Assistance